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Succinate dehydrogenase gene (SDHx) mutations increase susceptibility to develop pheochromocytomas/
paragangliomas (PHEOs/PGLs). In the present study, we evaluate the performance and clinical applications of 1H
high-resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR) spectroscopy–based global
metabolomic profiling in a large series of PHEOs/PGLs of different genetic backgrounds. Eighty-seven PHEOs/
PGLs (48 sporadic/23 SDHx/7 von Hippel-Lindau/5 REarranged during Transfection/3 neurofibromatosis type 1/1
hypoxia-inducible factor 2α), one SDHD variant of unknown significance, and two Carney triad (CTr)–related tumors
were analyzed by HRMAS-NMR spectroscopy. Compared to sporadic, SDHx-related PHEOs/PGLs exhibit a
specific metabolic signature characterized by increased levels of succinate (P b .0001), methionine (P = .002),
glutamine (P = .002), and myoinositol (P b .0007) and decreased levels of glutamate (P b .0007), regardless of their
location and catecholamine levels. Uniquely, ATP/ascorbate/glutathione was found to be associated with the
secretory phenotype of PHEOs/PGLs, regardless of their genotype (P b .0007). The use of succinate as a single
screening test retained excellent accuracy in distinguishing SDHx versus non–SDHx-related tumors (sensitivity/
specificity: 100/100%). Moreover, the quantification of succinate could be considered a diagnostic alternative for
assessing SDHx-related mutations of unknown pathogenicity. We were also able, for the first time, to uncover an
SDH-like pattern in the two CTr-related PGLs. The present study demonstrates that HRMAS-NMR provides
important information for SDHx-related PHEO/PGL characterization. Besides the high succinate–low glutamate
hallmark, SDHx tumors also exhibit high values of methionine, a finding consistent with the hypermethylation
pattern of these tumors. We also found important levels of glutamine, suggesting that glutamine metabolism
might be involved in the pathogenesis of SDHx-related PHEOs/PGLs.
Neoplasia (2015) 17, 55–65Introduction
Pheochromocytomas/paragangliomas (PHEOs/PGLs) are characte-
rized by high genetic heterogeneity—more than 14 different well-
studied genes have been linked to the development of these tumors.
Current genetic testing identifies pathogenic mutations in one third
or more of cases. Of all the known genetic mutations, deleterious
mutations in any of the succinate dehydrogenase (SDH) genes
(collectively named SDHx-associated tumors) are currently the
leading genetic cause of head and neck PGLs and account for more
than 30% of all hereditary cases. The four SDHx genes encode the
four subunits of the SDH enzyme (also named mitochondrial
complex II). This membrane complex catalyzes the oxidation of
succinate to fumarate in the tricarboxylic acid (TCA) cycle and the
respiratory chain. In SDHx mutation carriers, tumorigenesis requires
a second hit process (biallelic inactivation) that invariably results in
decreased SDH activity and/or a significant reduction or complete
absence of its protein. For the index cases, genetic testing is often
needed to implement personalized medical approaches [1]. A great
benefit of genetic testing also comes from evaluating family members
since they are potentially at risk of developing tumors, often multiple
and metastatic ones.
Until present, the choice of which genes to be tested has been
guided by clinical presentation and ex vivo biomarkers. Immunohis-
tochemistry can be very well used to show the presence or absence of
protein products [2,3]. Metabolomics, or global metabolite profiling,which is a new technology of functional genomics, can be used for
investigating metabolite changes associated with some gene mutations
[4]. Currently, well-recognized tools for metabolomics are nuclear
magnetic resonance (NMR) spectroscopy and gas chromatography–
mass spectrometry (GC-MS) or liquid chromatography (LC)–MS.
GC-MS and LC-MS are more widely represented in the technical
platforms referred to as metabolomics, mainly due to their high
sensitivity [5]. These technologies generate massive amounts of data
that can be interpreted and used for building predictive models. For
this purpose, machine-learning algorithms represent potent and
useful instruments to reduce the complexity of the data analysis.
Among NMR techniques, 1H high-resolution magic angle spinning
(HRMAS) NMR spectroscopy technology is especially suited to
analyze a small volume of intact tissue samples while avoiding any
chemical extraction procedures or sample manipulation, which are
necessary for both MS and liquid-state NMR or well-established
immunohistochemistry. HRMAS NMR enables rapid (3-4 minutes
for tissue sample preparation followed by 10 minutes of spectra
acquisition) and reliable identification and quantification of several
metabolites from spectra with excellent resolution and signal-to-noise
ratio. Recently, metabolomics has proven to be a promising tool in
the characterization PHEO/PGL [6–10].
The aim of the present study was to investigate the HRMAS
NMR-based metabolomic profiling of PHEOs/PGLs to 1) confirm
the accuracy of the previously described metabotype pattern based on
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(GSH), and ATP] in the diagnosis of SDH-related PHEO/PGL in a
large cohort of tumors with different genetic backgrounds, 2) define
the global metabolomic profile of the SDH-related PHEOs/PGLs in
comparison to sporadic tumors, and 3) identify metabolites that could
be used as clinical predictors of SDH deficiency even in PHEOs/
PGLs without any germline or somatic susceptibility gene mutations.Materials and Methods
Patients and Tumors
Eighty-seven specimens of PHEOs and PGLs of sympathetic origin
obtained from 79 unrelated patients were retrospectively selected in this
study according to the following criteria:
1. Histologic diagnosis of PGL/PHEO
2. Genetic screening for germline mutations in the SDH subunits B/C/D (SDHB/
C/D) (including large gene rearrangements of all the SDH genes), von Hippel-
Lindau (VHL) (including large gene rearrangements), neurofibromatosis type 1
(NF1) (in the presence of clinical features), REarranged during Transfection
(RET) (in the presence of hypercalcitoninemia), transmembrane-encoding gene
TMEM127, and MYC-associated factor X genes
3. Absence of systemic anticancer therapy before surgery
4. Tissue specimens collected during surgery just after tumor removal and snap-
frozen in liquid nitrogen before storage at −80°C.
The tumors were obtained from three different institutions in France
(Strasbourg, Marseille, and Nancy University Hospitals) and were
distributed as follows: 48 sporadic (42 PHEOs, 6 sympathetic PGLs), 23
SDHx (5 PHEOs, 18 sympathetic PGLs), 7 VHL (5 PHEOs, 2
sympathetic PGLs), 5 RET (PHEOs), 3NF1 (PHEOs), and 1 hypoxia-
inducible factor 2α (EPAS1/HIF2A) (sympathetic PGL). The 23 samples
of SDHx tumors were obtained from 23 distinct tumors belonging to 15
patients and were distributed as follows: 9 SDHB and 14 SDHD.
Data were acquired under regular clinical care conditions, with Ethics
Committee approval obtained for the use of these data for scientific
purposes. Written informed consent was obtained from all patients
included in the present study.
HRMAS NMR Spectroscopy
HRMAS NMR spectra were recorded on a Bruker Avance III 500
spectrometer operating at a proton frequency of 500.13MHz, installed at
the Pathological Department of Strasbourg University Hospital. The
amount of frozen tissue used for NMR analysis ranged from 15 to 20mg.
A one-dimensional (1D) proton spectrum using a Carr-Purcell-
Meiboom-Gill (CPMG) pulse sequence with presaturation of the water
signal was acquired for each sample. 1D HRMAS NMR spectra were
bucketed into integral regions 0.01 ppm wide (ppm range, 1-8.65) using
AMIX 3.8 software (Bruker GmbH, Rheinstetten, Germany) and
exported into SIMCA P (version 11.0; Umetrics AB, Umeå, Sweden).
To confirm resonance assignments, two-dimensional (2D) hetero-
nuclear (1H-13C) experiments were also recorded immediately after the
end of 1D spectra acquisition. Because the duration of these experiments
is long and tissue degradation occurs duringNMR acquisition, only a few
representative samples were analyzed by 2D experiments. Metabolites
were assigned using standard metabolite chemical shift tables available in
the literature [11,12].
Metabolite quantification has been previously described [6]. Briefly,
quantification was performed using an external reference standard of
sodium lactate, scanned under the same analytical conditions. Spectrawere normalized according to sample weight. Peaks of interest were
automatically defined by an in-house program using MATLAB 7.0
(Mathworks, Natick, MA). Peak integration was then compared to the
one obtained with the lactate reference andwas corrected according to the
number of protons. For our experiments, only peaks that were well
resolved in 1D CPMG spectra were quantified. Quantification results
were expressed as nmol/mg of tissue.
Statistical Analysis
A combination of principal component analysis (PCA) and
orthogonal partial least square discriminant analysis (OPLS-DA)
was herein adopted. The PCA was performed to evaluate the quality
of the data and to identify possible outliers [13]. Then, the OPLS-DA
was employed to optimize the separation between tumor subgroups.
The following two-class models of OPLS-DA were built in this study:
1. SDHx (n = 23) versus non-SDHx PHEOs/PGLs (n = 64) including sporadic,
VHL, RET, NF1, and HIF2A tumors. This analysis was performed to confirm
our previous results achieved in a smaller cohort of patients [7] and obtained
from the analysis of spectral intervals corresponding exclusively to four selected
metabolites with a possible key role in tumoral development. Accordingly,
succinate, glutamate, GSH, and ATP were identified and used in the model.
Succinate amount was estimated by integrating the area comprised between
2.39 and 2.43 ppm, glutamate quantity between 2.32 and 2.38 ppm, GSH
amount between 2.93 and 2.98 ppm, and ATP amount within the range of
6.07 to 6.11 ppm.
2. SDHx (n = 23) versus sporadic PHEOs/PGLs (n = 48). Seventy-one selected
tumor samples were included in this model to assess the global metabolic
fingerprint of SDHx-related PHEOs/PGLs in an exploratory and untargeted
manner. Accordingly, the full spectrum that ranged from 1 to 8.65 ppm was
analyzed and considered in the statistical model. In this case, the OPLS-DA was
performed on the whole set of metabolites (variables) to select those with a real
discriminating power. Metabolites corresponding to variable importance for
projection (VIP) value ≥1 were selected and labeled VIP metabolites. Two
measurements of model quality were reported for OPLS-DA: R2Y and Q2
representing, respectively, the goodness of fit (i.e., data variation) and the
goodness of prediction, as estimated by cross-validation. Q2 ≥ 0.5 can be
considered as a good predictor [14].
Cross-validation was used in each OPLS-DA model to determine the
number of components and to avoid overfitting the data. A cross-
validation embedded in a Monte Carlo resampling approach [15,16] was
used during the construction of the model to build a confusion matrix
that allowed a direct visualization of the performances of the model in
terms of classification power [sensitivity (Se), specificity (Sp), positive
predictive value (PPV), negative predictive value (NPV), and global
accuracy]. The SIMCA P (version 11.0; Umetrics AB) package was used
for statistical data analysis.
Continuous variables are expressed as mean ± SD. Statistical analysis
was performed using IBM SPSS Statistics version 20 (IBM SPSS Inc,
Chicago, IL). The Spearman non-parametric test was performed to
determine the correlation between metabolites. Comparisons of tumor
metabolite concentrations between SDHx-related and sporadic tumors
were performed using a Mann-Whitney U test. The receiver operating
characteristic (ROC) curves were used to evaluate the clinical utility of
metabolite quantification in the diagnosis of SDHx mutation. Areas
under the ROC curve, sensitivity, and specificity were determined using
MedCalc version 13.2.2 (MedCalc Software, Ostend, Belgium).
According to the ROC curve, values exhibiting the best accuracies were
chosen as the threshold for a screening test. Linear regression model was
used to examine the association between metabolite levels and genetic
status with adjustment for tumor location and total catecholamine levels
58 Metabolomics in PHEOs/PGLs Imperiale et al. Neoplasia Vol. 17, No. 1, 2015as explanatory variables. For multiple testings, adjusted P values were
calculated using the false discovery rate (FDR) procedure with the SAS
PROC MULTTEST statement [17]. PCA was performed to visualize
and analyze correlations between metabolite concentrations and SDHx
status. PCA was done using the package FactoMiner (Multivariate
Exploratory Data Analysis and Data Mining with R). Values of P b .05
were considered to be statistically significant.
Network Analysis
The Algorithm to Determine Expected Metabolite Level Alter-
ations Using Mutual Information (ADEMA) has been applied [18].
Instead of analyzing metabolites one by one, the algorithm assesses
the changes in groups of metabolites, between the case and the
control. It incorporates the metabolic network topology to determine
the groups of metabolites. ADEMA uses mutual information to 1)
find out if those metabolites are biomarkers when considered together
and 2) predict the expected direction of change per metabolite, when
metabolic network topology is considered.
Figure 2 shows the simplified metabolic subnetwork we have used
to relate metabolites. The network was constructed using Kyoto
Encyclopedia of Genes and Genomes (KEGG) [19,20] and the work
of Selway et al. [21] On the basis of the network, the following
metabolite groups were obtained:
• aspartate, succinate, glutamate, glutamine, ATP
• methionine, myoinositol, ascorbate, noradrenaline, adrenaline, ATP
• myoinositol, ascorbate, methionine, taurine, ATP
• noradrenaline, adrenaline, total catecholamines, ATP
• myoinositol, ascorbate, noradrenaline, adrenaline, total catecholamines, ATP.
For discretization of metabolite observations, we have set number of
levels (M) as 6 and number possible levels an observation assigned to (k) as
4. Missing metabolite observations were amputated using the average
measurement value for that metabolite. Using the abovementioned
metabolite groups and parameters, an expected metabolite level for case
and for control is obtained per metabolite. The direction of the expected
change is obtained by comparing expected levels (e.g., SDHx vs sporadic
PHEOs/PGLs).
Results
SDHx versus Non-SDHx PHEOs/PGLs
At visual inspection, all the spectra obtained from the 87 analyzed
tumor samples were of good quality without any prominent hallmarks
of tissue necrosis or cystic components. The generated multivariate
one-component OPLS-DA based on succinate, glutamate, GSH, and
ATP allowed a clear separation of SDHx from non-SDHx PHEOs/
PGLs showing accurate representation of the data and a good
cumulative confidence criterion of fit (R2Y =0.65) and prediction
(Q2 = 0.64). These results are graphically represented in Figure 1.
Nineteen of 23 patients with SDHx-related PHEOs/PGLs were
correctly identified. Moreover, all 64 patients with non–SDHx-
related PHEOs/PGLs were accurately classified. To detect patients
with SDHx germline mutations, the Se and Sp of the established
model were 83% and 100%, respectively. PPV, NPV, and global
accuracy were 100%, 94%, and 95%, respectively.
No significant spectrum overlap that prevented quantification of
succinate, glutamate, GSH, and ATP was found. All NMR spectra from
the SDHx-related PHEOs/PGLs showed significantly high levels of
succinate (4.01 ± 2.45 nmol/mg vs 0.06 ± 0.06 nmol/mg, P b .00001)and lower concentration of glutamate (0.70 ± 0.41 nmol/mg vs 1.60 ±
0.76 nmol/mg, P b .00001) compared to those of sporadic tumors and
PHEOs/PGLs related toVHL,RET,NF1, andHIF2mutations. Neither
GSH nor ATP amount was significantly different between the SDHx-
and non–SDHx-related PHEOs/PGLs (Figure 1). Interestingly, the four
SDHx-related tumor samples, which were incorrectly classified by the
previous OPLS-DA model, showed significantly lower amounts of
succinate (P = .003) and higher concentrations of glutamate (P = .003)
than the remaining 19 SDHx-related PHEOs/PGLs [7].
SDHx versus Sporadic PHEOs/PGLs
Twenty-three SDHx-related PHEOs/PGLs and 48 sporadic tumors
were included in the analysis. A total of 24 metabolites was recognized
from the spectra obtained from all 71 tumor samples within the range of 1
to 8.65 ppm (Supplementary Table 1). Besides peaks due to small water-
soluble molecules, the acquired spectra display consistent broad
resonances, which were attributed to three different fatty acid moieties
defined as a, b, and c [22]. A two-component OPLS-DA showed a very
clear separation of the two sets of samples, a faithful representation of the
Y data (R2Y =0.82) and a good cumulative confidence criterion of
prediction (Q2 = 0.7). These results are graphically represented in
Figure 1.When comparing sporadic to SDHx-related tumors, the OPLS-
DA model accurately classified all samples. Examples of 1D HRMAS
CPMG spectra obtained from sporadic and SDHD-related PGL are
represented in Supplementary Figure 2.
According to the results of the OPLS-DA model, 12 VIP metabolites
were identified. A higher level of succinate, myoinositol, methionine,
glutamine, taurine, and ATP characterized SDHx-related PHEOs/PGLs,
while sporadic tumors contained a larger amount of adrenaline,
noradrenaline, glutamate, GSH, ascorbate, and aspartic acid (Figure 1).
The quantity of the 12metabolites previously listed was assessed and used
for tumor comparison according to the genetic background. When
compared to sporadic phenotypes, the metabolomic profile of SDHx-
related tumors exhibits statistical significance in the following areas:
1. Increased levels of succinate (4.01 ± 2.45 nmol/mg vs 0.06 ± 0.06 nmol/mg,
P b .0001), taurine (2.59 ± 1.35 nmol/mg vs 1.66 ± 1.43 nmol/mg, P = .002),
methionine (0.09 ± 0.04 nmol/mg vs 0.04 ± 0.04 nmol/mg, P b .0001),
glutamine (0.37 ± 0.24 nmol/mg vs 0.23 ± 0.16 nmol/mg, P = .12), and
myoinositol (3.18 ± 1.43 nmol/mg vs 1.87 ± 1.49 nmol/mg, P b .0001).
2. Decreased levels of aspartate (0.32 ± 0.50 nmol/mg vs 0.50 ± 0.27 nmol/mg,
P b .0001), glutamate (0.71 ± 0.41 nmol/mg vs 1.64 ± 0.78 nmol/mg,
P b .0001), and adrenaline (0.10 ± 0.43 nmol/mg vs 1.17 ± 2.18, P b .001)
(Supplementary Tables 2 and 3).
In spite ofGSH,ATP, catecholamines, and ascorbate playing a role in
tumor classification in the OPLS-DA model, their amounts were not
statistically different between SDHx-related PHEOs/PGLs and sporadic
tumors when compared using a standard non-parametric univariate test.
Interestingly, after adjustment for tumors, total catecholamine content,
and tumor location (adrenal and extra-adrenal), succinate (P b .0001),
methionine (P = .002), glutamate (P b .0007), glutamine (P = .002), and
myoinositol (P b .0007) remained statistically different between the two
groups (Supplementary Table 3). Correlations between variables are
represented in Supplementary Table 4. The importance of the different
metabolites regarding their correlations with the mutation status is
illustrated in Supplementary Figures (Supplementary Figure 1).
When the data are analyzed using ADEMA, using the metabolic
subnetwork depicted in Figure 2, the following results were obtained.
ADEMA has predicted a higher level of succinate, myoinositol,
Figure 1. Results of three-component OPLS-DAmodels and the corresponding loading plots according to the patient’s genotypes: (A and
B) SDHx (n = 23) versus non-SDHx PHEOs/PGLs (n = 64), including sporadic, VHL, RET, NF1, and HIF2 tumors, and based on succinate,
glutamate, GSH, and ATP; (C and D) SDHx (n = 23) versus sporadic PHEOs/PGLs (n = 48) and based on the whole tumoral metabolome.
For this OPLS-DAmodel, the loading plot represents only the 12metabolites with the higher discriminant power (VIP metabolites). A clear
distinction between the different classes of tumors is shown in both models.
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while sporadic tumors contained a higher amount of adrenaline,
glutamate, GSH, and total catecholamines (Figure 2). ATP, noradren-
aline, ascorbate, GSH, and aspartate are predicted to be equivalent among
cases and controls. Results show that network and mutual information-
based analysis is in accordance with the statistical significance of changes
shown above (Supplementary Table 3), with the exception of aspartate.
Aspartate is predicted to be same in both groups by ADEMA.
Quantification of Succinate Concentration as a Screening
Method for SDH Mutation
The use of succinate as a single screening test showed higher accuracy
when compared to other metabolites and a combination of metabolites
for distinguishing SDHx versus non–SDHx-related tumors (including
sporadic, VHL,MEN2, and HIF2A tumors; Figure 3 and Table 1) and
SDHx-related tumors versus sporadic ones (Figure 3 and Table 1). As
shown in Figure 4, tumors with high succinate levels had a high
probability of belonging to an SDHx patient. The optimal succinate
cutoff was 0.253 nmol/mg for distinguishing SDHx versus any non-
SDHx tumors and 0.096 nmol/mg to discriminate between SDHx and
sporadic tumors. With these threshold points, Se and Sp were 100% in
both situations. Interestingly, the four SDHx-related PHEOs/PGLs thatwere incorrectly classified by the OPLS-DA model built on the whole
studied population showed a succinate value higher than the diagnostic
threshold established by ROC curve analysis, leading to correct tumor
identification. To discriminate SDHx-related from sporadic PHEOs/
PGLs, ROC curves were also built using the quantitative values of
glutamate, methionine, myoinositol, and methionine/glutamate ratio.
However, the diagnostic accuracy obtained for each single metabolite was
lower than the accuracy achieved by succinate as a single tumor
biomarker. The cutoff of 0.742 nmol/mg for glutamate, 0.045 nmol/mg
for methionine, and 2.383 nmol/mg for myoinositol provided
suboptimal values of Se and Sp in both cases (Se = 86.9% and Sp =
89.5% for glutamate; Se = 95.6% and Sp = 62.5% for methionine; and
Se = 73.9%and Sp= 81.2% formyoinositol). Finally, considering 0.0524
nmol/mg as the diagnostic threshold for methionine/glutamate ratio, Se
and Sp were 91.3% and 89.6%, respectively (Figure 3 and Table 1).
Quantification of Succinate Concentration as a Functional Test for
Evaluating SDHx Mutation of Unknown Pathogenicity
We report the case of a 55-year-old male who was evaluated for
bilateral carotid body PGLs (CBPGLs). At the initial examination,
there was no family history of any PGL. Plasma/urinary metane-
phrines and serum chromogranin A were normal. Both PGLs were
Figure 2.Metabolic subnetwork showing the results of theADEMAanalysis that comparesSDHx (n=23) versus sporadicPHEOs/PGLs (n=64).
Red arrows show metabolites that are predicted to increase, green arrows show metabolites that are predicted to decrease, and blue arrows
show metabolites that are expected to stay the same, between two groups, respectively.
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xyphenylalanine positron emission tomography/CT (Figure 4, A
and B). Genetic testing revealed a deletion of six nucleotides in exon
4 of the SDHD gene (c.433_438del), resulting in a deletion of two
amino acids (p.His145_Asp146del, Δ145,146). This allelic variant,
never reported in the literature, was classified as of unknown
significance according to in silico analysis. Both CBPGLs were
removed and histopathology confirmed the diagnosis. Investigating
the pathogenicity of this mutation, HRMAS NMR spectroscopy of
an intact tissue sample showed an increased succinate concentration
(0.378 nmol/mg) consistent with an SDH dysfunction (Figure 4C ).
Furthermore, SDHB immunohistochemistry (Figure 4D) and
homology modeling with MODELLER (Figure 4E ) further
supported the pathogenicity of this mutation. After the diagnosis,
the patient’s sister was found to have bilateral PHEOs and
HNPGLs, further supporting the diagnosis of a hereditary PGL in
these family members.Quantification of Succinate Concentration in a Case of
Carney Triad
We report HRMAS NMR spectroscopy findings in two extra-adrenal
PGLs obtained from a single Carney triad (CTr) patient. The clinical case
was previously reported [23]. Briefly, the diagnosis of CT was based on
the following criteria: young female patient (18 years at diagnosis), no
family history, two extra-adrenal PGLs of sympathetic origin (one
thoracic and one abdominal), multiple gastric Gastrointestinal Stromal
Tumor (GIST), and an absence of mutations in any of the SDH genes
(including large deletions). HRMAS NMR spectra obtained from the
analysis of both PGLs are represented in Figure 5 and are uniquely
consistent with an SDH mutation–like pattern, showing an important
succinate peak corresponding to a succinate amount of 1.91 and
4.63 nmol/mg, respectively.Discussion
The present study shows that HRMAS NMR spectroscopy is a very
reliable method for classifying various PHEOs/PGLs according to their
genetic background [7]. Such a metabolomics-based approach allows for
the detection of metabolic changes (biomarkers) that are specifically
related to a medical condition (e.g., SDHx-related mutation), resulting in
diagnostic and potential prognostic implications. In our study, HRMAS
NMR spectroscopy allowed for the exploratory investigation of the global
metabolic phenotype of SDHx-related PHEOs/PGLs, leading to the
identification of several specific biochemical alterations.
First, we described the whole metabolome findings of SDHx-
related PHEOs/PGLs and found that several metabolites do not
belong to the Krebs cycle, such as methionine/taurine, glutamate/
aspartate, and myoinositol.
Moreover, we found that the assessment of succinate concentration
can be clinically relevant as a single metabolic biomarker for
discriminating SDHx-related tumors from sporadic and other
hereditary PHEOs/PGLs. Thus, HRMAS NMR spectroscopy
could be used as a reliable screening method for the indication of
whether sequencing of one of the SDH genes should be initiated.
Furthermore, the present study also documents that SDHxmutations
with unknown pathogenicity could be reclassified by this approach.
Finally, in PHEOs/PGLs where a genetic abnormality is highly
expected, although leading to the disappearance of SDH protein (e.g.,
patients with Carney triad), HRMAS NMR spectroscopy can nicely
point to such a protein abnormality and could lead to a narrow search
for specific genes of this and other cancers.
The role of MS in the diagnosis of SDHx-related tumors and for
functional analysis of SDH variants has been recently reported in a large
population of patients [9]. Although MS is characterized by a superb
sensitivity, it also has some disadvantages. The chemical extraction
procedure before tissue sample examination represents a crucial question.
Perchloric acid extraction should be avoided because of significant
Figure 3. ROC curves obtained from analysis of the succinate, glutamate, methionine, glutamine, and myoinositol concentrations for the
diagnosis of SDHxmutation. Detailed information about the area under the ROC curve, the cutoff values, sensitivity, and specificity are shown.
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reproducible nor resolvable asGCand it is perhaps the slowest (1 to 2 days
per sample) of all three methods, including GC-MS and NMR
spectroscopy. Finally, LC-MS is not really quantitative and is often
designed to simply detect the presence or absence of a molecule rather
than to assess its concentration [24]. Furthermore, immunohistochem-
istry (IHC) for SDH tumors, although currently very popular and
reliable, first requires sample processing and, second, an experienced
technician and pathologist to minimize false-positive or false-negativeinterpretations. Moreover, this technique provides a limited view of a
tumor’s biology, usually assessing only one protein at a time and in a
semiquantitative manner. In contrast, HRMAS NMR allows for rapid
and reproducible quantification of several metabolites (proteins) from
only 15 mg of intact tissue, requiring only about 1 hour to prepare the
tissue sample, collect data, and analyze the results. Nevertheless, similar to
other approaches, experienced staff are required to interpret results.
However, compared to othermethodsmentioned above,HRMASNMR
spectroscopy provides new insights into the understanding of tumor
Table 1. Performances of Succinate, Methionine, and Glutamate Concentrations in the Diagnosis of SDHx Mutation
Se (95% CI) Sp PPV NPV Accuracy
Succinate N 0.253 (SDHx vs non-SDHx) 100% (85.2-100) 100% (94.4-100) 100% (85.2-100) 100% (94.4-100) 100% (95.8-100)
Succinate N 0.0962 (SDHx vs sporadic) 100% (81.5-100) 100% (54.1-100%) 100% (81.5-100) 100% (54.1-100) 100% (86.2-100)
Glutamate ≤ 0.7426 (SDHx vs sporadic) 86.9% (66.4-97.2) 89.6% (77.3-96.5) 80.0% (60.9-91.1) 93.5 (82.5-97.8) 88.7 (79.3-91.2)
Methionine N 0.045 (SDHx vs sporadic) 95.7% (78.1-99.9) 62.5% (47.4-76.1) 55% (38.5-70.7) 96.8% (83.3-99.9) 73.2% (61.9-82.2)
Glutamine N 0.222 (SDHx vs sporadic) 73.9% (51.6-89.9) 62.5% (48.4-74.8) 48.6% (32.9-64.4) 83.3% (68.1-92.1) 66.2% (54.6-76.1)
Myoinositol N 2.3837 (SDHx vs sporadic) 73.9% (51.6-89.8) 81.3% (68.1-89.9) 65.4% (46.2-80.6) 86.7% (73.8-93.7) 78.9% (68.0-86.8)
Methionine/glutamate N 0.0524 (SDHx vs sporadic) 91.3% (72.0-98.9) 89.6% (77.3-96.5 80.8% (62.1-91.5) 95.6% (85.2-98.8) 90.1% (81.0-95.1)
CI, confidence interval.
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associated with unique cancer metabolome and behavior, including
SDHx mutations.
In the present study, except for well-known changes in tumor succinate
levels, high methionine and low glutamate/aspartate were found to be
associated with SDHx deficiency. Recently, it has been shown that
SDHx-related tumors exhibited a hypermethylated phenotype [25].Figure 4. HRMAS NMR spectra from a tumor with SDHD mutatio
fluorodihydroxyphenylalanine PET/CT (B) showing a CBPGL. Succin
Absence of significant SDHB immunostaining on tumor cells (D). Cart
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adenosyl methionine, which is a methyl donor for numerous reactions of
methylation, includingDNA. Themechanisms involved in the reduction
of glutamate/aspartate in SDHx-mutated tumors are largely unknown
and might be related to an inhibition of the membrane transport of these
amino acids or a decrease in their synthesis due to a TCA defect. It hasn of unknown pathogenicity. Contrast-enhanced CT (A) and 18F-
ate peak on 1D HRMAS CPMG spectrum NMR spectroscopy (C).
oon representation of the 3D models of Wild Type (WT) (E, left) and
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a small loop between H3 (yellow orange) and H4 (reddish) helices
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Figure 5. 1D and 2D HRMASNMR spectra obtained from the analysis of Carney triad–related thoracic and abdominal PGLs developed in a
single patient. The metabolic content in 1D spectra (A, B) can be directly compared since the intensity of each spectrum was normalized
with respect to the weight of each examined sample. The two Carney triad–related tumors show an obvious peak of succinate-like SDHx-
related PGL phenotype, suggesting a dysfunction of the SDH complex in both cases. The increase of lactate and fatty acids, which is
pronounced in Carney triad–related PGLs, suggests necrotic involution of tumor, probably associated with a prolonged time of ischemia
after surgery and is independent from succinate accumulation. 2D spectra (C) with zoom on the succinate region (D) were obtained from
the thoracic PGL and confirm the important accumulation of succinate in tumoral tissue. Succinate assignment is indicated.
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glutamate transporters, including the glutamate aspartate transporter.
DNA methylation has also been shown as a potential mechanism for
silencing the human glutamate transporter [26]. Evaluation of the
expression of glutamate aspartate transporter and other glutamate
transporters in SDHx-related PGL in comparison to sporadic cases
would be of particular interest. We also found an increase of glutamine
levels in SDHx-related tumors. The microarray study showed a
significantly higher concentration of glutamine transporter SLC3A2
mRNA. We suggest that glutamine metabolism is involved in the
pathogenesis of SDHx-related PHEOs/PGLs [27].
Glutaminolysis is an anaplerotic pathway of the TCA cycle and
supports the production of antioxidant molecules [28–30]. Myoinositol
was found to be associated with SDH status and catecholamine levels.
Myoinositol is a six-carbon alcohol easily detected in HRMAS NMR
spectra. Therefore, it could be potentially used as a biomarker. The
relationship between SDH and myoinositol is largely unknown, but it is
possible that SDHx-related tumors participate in the activation of
myoinositol signaling pathways.
When compared to sporadic phenotypes, the metabolomic profile
of SDHx-related tumors exhibits decreased levels of adrenaline.
SDHx-related tumors have been previously found to be associated
with lower catecholamine content.
ATP, ascorbate, and GSH were found to be associated with the
secretory phenotype. This secretory machinery, which includes neuro-transmitter uptake and storage in vesicles and exocytosis, requires ATP—
a finding that has been found on NMR spectra. A high rate of glucose
uptakemight be necessary to fulfill this high ATP demand. Interestingly,
ATP production is not impaired in the presence of SDH deficiency. It is
therefore possible that TCA remains partially functional and enables,
together with glycolysis, the production of NADH. The electrons, born
on NAD1 (nicotinamide-adenine dinucleotide), are transferred to
respiratory complex I (NADH dehydrogenase) and then to coenzyme
Q10. From coenzyme Q10, the electrons are passed to complex III.
Therefore, ATP production remains possible through the electron
transport chain (ETC) despite inactivation of complex II of the
respiratory chain.
PHEOs/PGLsmay also highly accumulate ascorbate since human cells
do not synthesize it. Ascorbate accumulation in cells can occur through
two different mechanisms. The sodium-dependent vitamin C trans-
porters can transport ascorbate in a sodium-dependent fashion. In adrenal
tissues, only sodium-dependent vitamin C transporter 2 is present [31].
The other possibility is that dehydroascorbic acid (DHA) can be
accumulated through various glucose transporters (GLUT1, for
example). DHA undergoes rapid reduction in the intracellular
environment (through GSH, thioredoxin, or other NADPH-dependent
processes), leading to ascorbate accumulation. However, significant
oxidation of ascorbate in the extracellular environment would need to be
present to generate the DHA necessary to explain the high intracellular
ascorbate levels found in the tumors. It is unclear whether there is a direct
64 Metabolomics in PHEOs/PGLs Imperiale et al. Neoplasia Vol. 17, No. 1, 2015explanation for the high ascorbate levels in some tumors. In the present
study, we found that ascorbate was correlated with total catecholamine
concentrations. This finding could be explained by the role of ascorbate as
a cofactor in the conversion of dopamine to norepinephrine. Oxygen is
also a co-factor in that reaction, consistent with the idea that the tumors
are not hypoxic.
GSH is the most abundant endogenous antioxidant protein and
therefore plays a critical role in the regulation of oxidative stress.
We have found GSH to be correlated with total catecholamine levels.
o-Quinones are physiological oxidation products of catecholamines
that contribute to redox cycling, toxicity, and apoptosis. Therefore,
GSH conjugation of these oxidized metabolites (o-quinones) through
GSH transferases is a detoxification reaction that prevents redox
cycling, thus indicating that GSH and GSH transferases have a
cytoprotective role involving elimination of reactive chemical species
originating from the oxidative metabolism of catecholamines [32].
When we have analyzed our observations using a mutual
information and metabolic network–based analysis, called ADEMA,
we have seen that the algorithm has predicted changes that are in
accordance with the hypotheses given above. This shows that the
results are also robust with respect to the dependencies within the
topology of the metabolic network.
Metabolomics may also illustrate the SDH dysfunction that may
occur in the absence of an SDH mutation. This is the case for Carney
triad. Carney triad, originally described by J. Aidan Carney in 1977,
associates tumors in at least two of the five following organs in the
same patient: stomach (gastric gastrointestinal stromal tumor), lungs
(pulmonary chondroma), paraganglionic system (extra-adrenal PGL),
adrenal cortex (adenoma), and esophagus (leiomyoma) [33]. At
present, a specific genetic mutation has not been discovered with CT;
however, very few patients were found to have SDHx genetic
mutations. Recently, DNA methylation at the gene locus of the
SDHC has been found in CT-related tumors, leading to loss of the
SDHC protein [34]. In the present study, we found that Carney triad
was associated with SDH deficiency. Therefore, in the presence of
high succinate/no SDHx mutation, the possible diagnosis of CT
should be raised and patients should undergo screening for other CT-
related tumors, especially gastric gastrointestinal stromal tumor that
may affect long-term survival in CT patients.
Conclusions
The present study, which includes a large number of PHEOs/PGLs,
shows that HRMAS NMR spectroscopy provides unique and accurate
information in the metabolomic classification of these tumors.
Furthermore, this approach also advances our knowledge of the
pathogenesis of PHEOs/PGLs. It is also expected that many of these
metabolomic approaches, along with the latest improvements, will
reveal new targets for future therapeutic options. Recent introduction of
cryogenic probes has already improved spectral signal-to-noise ratios by
up to a factor of five, reducing the gap betweenHRMASNMR andMS
[35]. In comparison to 1D 1H-NMR spectroscopy, 2D techniques
based on proton scalar coupling are further improving both detection
sensitivity and metabolite identification, especially when specific
metabolite-related picks are overlapped in 1D NMR acquisitions.
Moreover, it is nowadays possible to quantifymetabolites on 2D spectra
[36]. However, the large centrifugal forces applied to the biologic
sample during several hours of 2D NMR acquisition have a direct
consequence on tissue integrity, which could potentially influence
results [37].The present study well justifies that, in the near future, functional
genomics will allow for and perfect the identification of tumor-specific
metabolic biomarkers as well as their genetics. It is expected that cancer
metabolomes will be quickly implemented in new diagnostic and
treatment options of various cancers as well as their prognosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.10.010.
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